8-K: Pulse Biosciences Secures $60M ATM Equity Facility

Pulse Biosciences entered a new equity distribution agreement with TD Securities (USA) LLC for up to $59,976,196 in common stock, replacing a prior facility.

Summary

• Pulse Biosciences, Inc. (the Company) entered into an equity distribution agreement (the Sales Agreement) with TD Securities (USA) LLC (TD Cowen) on February 19, 2026.
• The Sales Agreement allows the Company to offer and sell shares of its common stock with an aggregate offering price of up to $59,976,196 through TD Cowen as a sales agent.
• Sales will be made 'at the market' or through negotiated transactions, including block trades, at prevailing market prices or prices related to them.
• The Company will pay TD Cowen a commission rate of up to 3.0% of the gross sales price of any shares sold.
• The Company is not obligated to sell any shares under the Sales Agreement and can suspend solicitations at any time.
• The issuance and sale of shares will be made pursuant to the Company's effective registration statement on Form S-3 (File No. 333-278322) and a related Form S-3 (File No. 333-280805).
• A prospectus supplement was filed with the SEC on February 19, 2026, in connection with this offering.
• Prior to entering the new Sales Agreement, on February 18, 2026, the Company terminated its previous at-the-market offering program.
• As of its termination, the prior agreement, dated July 15, 2024, had up to $59,976,196 in common stock remaining unsold.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it secures a flexible funding mechanism for the company, which is crucial for ongoing operations and growth. However, the potential for shareholder dilution introduces a degree of caution.

Positives

• Provides a flexible and efficient mechanism for Pulse Biosciences to raise capital as needed, adapting to market conditions.
• Secures access to up to $59,976,196 in additional funding, enhancing liquidity and financial flexibility.
• The 'at the market' nature of the offering allows the Company to opportunistically raise funds without the need for a large, single underwritten offering.
• The termination of the prior agreement and establishment of a new one ensures continuity of this important financing option.

Negatives

• Potential for dilution of existing shareholders' ownership and earnings per share if new common stock is issued.
• The Company will incur commission fees of up to 3.0% of the gross sales price, reducing net proceeds.
• There is no obligation for the Company to sell shares or for the agent to purchase them, meaning the capital raise is not guaranteed.
• Potential for downward pressure on the share price if a significant number of shares are sold into the market over time.

Risks

• Dilution of existing shareholders' equity and potential decrease in earnings per share due to the issuance of new common stock.
• Potential for downward pressure on the Company's stock price if a substantial volume of shares is sold into the market.
• Uncertainty regarding the timing, volume, and pricing of future share sales, which are dependent on market conditions and the Company's discretion.
• Costs associated with the offering, including sales agent commissions of up to 3.0% and other legal and administrative expenses, will reduce the net proceeds received by the Company.

Future Outlook

The filing establishes a mechanism for future capital raises but does not provide specific guidance on the timing or amount of shares to be sold. The Company retains flexibility to sell shares from time to time based on its instructions and market conditions.

Management Comments

• Paul A. LaViolette, Chief Executive Officer, signed the report on behalf of Pulse Biosciences, Inc.

Industry Context

StockSavvy.ai notes that 'at-the-market' (ATM) offerings are a common and flexible capital-raising tool for publicly traded companies, particularly in sectors like biotechnology or medical devices. They allow companies to tap into equity markets opportunistically without the need for a large, single underwritten offering, which can be beneficial for companies with fluctuating capital needs or those seeking to minimize market disruption. This type of offering is often used by growth-stage companies or those requiring ongoing R&D funding.

Comparison to Industry Standards

• ATM offerings are a standard financing mechanism in the public markets, widely utilized across various industries.
• The commission rate of up to 3.0% for the sales agent is within the typical industry range for such agreements, which can vary from 1% to 5% depending on the size and complexity of the offering and the issuer's market capitalization.
• The filing does not provide specific comparable companies, projects, or results to benchmark against, as it is a procedural update on a financing facility rather than a performance report.

Stakeholder Impact

• Shareholders: Potential for dilution of existing equity and earnings per share if new shares are issued, but also benefits from enhanced company liquidity and funding for operations.
• Company: Gains a flexible and efficient mechanism for raising capital to support strategic initiatives and ongoing business needs.
• TD Securities (USA) LLC: Acts as the sales agent, earning commissions on any shares sold under the agreement.

Next Steps

• The Company may, from time to time, instruct TD Cowen to sell shares of common stock under the Sales Agreement.
• The Company will file required reports and notices with Nasdaq and the SEC related to any sales made under the agreement.

Key Dates

Keywords

Equity Distribution Agreement, ATM Offering, Capital Raise, Common Stock, Dilution, TD Securities, Nasdaq, SEC Filing, Pulse Biosciences